2024
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.Peer-Reviewed Original ResearchHigh-grade serous ovarian cancerClear cell carcinomaHER2-targeting antibody-drug conjugateAntibody-drug conjugatesT-DXdReceptor over-expressionTrastuzumab deruxtecanXenograft modelCell linesOvarian clear cell carcinomaOvarian cancer cell linesTumors overexpressing HER2Biologically aggressive tumorsFluorescence in situ hybridization assaySerous ovarian cancerEffective antibody-drug conjugatesIn vivo antitumor activityMouse xenograft modelMetastatic cell linesDS-8201aCancer cell linesAggressive tumorsHER2 expressionCell carcinomaOvarian cancer
2021
Miscellaneous Neoplasia of the Ovary
Hui P, Banet N. Miscellaneous Neoplasia of the Ovary. Practical Anatomic Pathology 2021, 283-295. DOI: 10.1007/978-3-030-68608-6_11.Peer-Reviewed Original ResearchMetastatic carcinomaOvarian malignant epithelial tumorsPrimary ovarian lymphomaUnknown cell originSmall cell carcinomaBilateral ovarian involvementPrimary ovarian carcinomasMalignant epithelial tumorsLow-grade appearanceBreast primaryOvarian lymphomaStromal luteinizationOvarian involvementTumor thrombusCell carcinomaOvarian tumorsPrimary carcinomaAggressive tumorsCystic appearanceHypercalcemic typeMetastatic tumorsOvarian carcinomaTumor nodulesEpithelial tumorsCarcinoma